MTOR and neoplasm: The management of the immunosuppression becomes very important in this setting not much for the introduction of mTOR inhibitors, which have not shown correlation with the post-recurrence survival, but because we need to find a balance between the graft protection and an immune system reactive against potential tumor cells circulating systemically.